Valuation: Mesoblast Limited

Market Cap 3.17B 2.21B 1.93B 1.78B 1.64B 3.1B 212B 21.27B 8.37B 104B 8.29B 8.11B 359B P/E 2026 *
-39.2x
P/E 2027 * 86.5x
Enterprise Value 3.14B 2.19B 1.92B 1.77B 1.63B 3.07B 211B 21.11B 8.31B 103B 8.23B 8.05B 356B EV / Sales 2026 *
17.4x
EV / Sales 2027 * 9.82x
Free-Float
64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Mesoblast Limited

1 day-11.91%
1 week+8.93%
Current month+24.81%
1 month+18.45%
3 months+8.44%
6 months-7.58%
Current year-10.29%
1 week 2.28
Extreme 2.28
2.78
1 month 1.88
Extreme 1.88
2.78
Current year 1.88
Extreme 1.88
3.31
1 year 1.88
Extreme 1.88
3.31
3 years 0.26
Extreme 0.255
3.37
5 years 0.26
Extreme 0.255
3.37
10 years 0.26
Extreme 0.255
5.7
Manager TitleAgeSince
Chief Executive Officer 69 2011-03-22
Director of Finance/CFO 59 2025-11-16
Chief Tech/Sci/R&D Officer - 2026-03-10
Director TitleAgeSince
Director/Board Member 69 2006-12-31
Director/Board Member 75 2013-04-14
Director/Board Member 78 2014-03-05
Date Insider Type Main position Quantity % Market Cap.
4/16/26 Buy

Director

700,000 0.0543%
4/16/26 Buy

Director

4,886,890 0.3787%
4/16/26 Buy

Director

2,324,072 0.1801%
Change 5-day change 1-year change 3-year change Capi.($)
-11.91%+8.93%+1.24%+78.10% 2.21B
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average -1.14%+0.92%+58.78%+96.17% 24.58B
Weighted average by Cap. -0.16%-0.10%+78.69%+122.88%

Financials

2026 *2027 *
Net sales 180M 126M 110M 101M 93.39M 176M 12.09B 1.21B 476M 5.93B 472M 461M 20.42B 311M 217M 190M 175M 161M 304M 20.88B 2.09B 823M 10.24B 814M 797M 35.26B
Net income -76.81M -53.54M -46.84M -43.24M -39.8M -75.06M -5.15B -516M -203M -2.53B -201M -197M -8.7B 47.76M 33.29M 29.13M 26.89M 24.75M 46.68M 3.2B 321M 126M 1.57B 125M 122M 5.41B
Net Debt -23.05M -16.06M -14.06M -12.98M -11.94M -22.52M -1.55B -155M -60.93M -758M -60.3M -58.98M -2.61B -110M -76.34M -66.8M -61.66M -56.75M -107M -7.35B -735M -290M -3.6B -287M -280M -12.41B
Logo Mesoblast Limited
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Employees
81
Date Price Change Volume
26-07-17 A$2.440 -11.91% 7,134,866
26-07-16 A$2.770 +6.95% 7,786,526
26-07-15 A$2.590 +8.82% 6,562,425
26-07-14 A$2.380 +1.28% 4,049,590
26-07-13 A$2.350 +4.91% 5,388,829
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.440AUD
Average target price
3.798AUD
Spread / Average Target
+55.64%

Quarterly revenue - Rate of surprise